← Back to Search

Fecal Microbiota Transplantation

Probiotics for Ulcerative Colitis

Phase 2
Recruiting
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult ≥18 years of age
Remission of UC based on clinical grounds (partial Mayo score of ≤2 with each subscore ≤1), and on stable maintenance therapy
Must not have
Females who are pregnant, breastfeeding, or planning to become pregnant during the study
Unable to take multiple capsules orally
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months

Summary

This trial is testing freeze-dried PRIM-DJ2727 capsules taken by mouth in people with ulcerative colitis who are not currently experiencing symptoms. The treatment might work by changing gut bacteria to help keep the disease from coming back.

Who is the study for?
Adults over 18 with Ulcerative Colitis in remission can join this trial. They must have had active UC within the last year, be on stable therapy, and agree to use birth control if applicable. Exclusions include other GI conditions, certain infections like HIV or Hepatitis B/C, compromised immune systems, recent FMT or investigational drugs, inability to take oral capsules, pregnancy/breastfeeding intentions during the study.
What is being tested?
The trial tests lyophilized PRIM-DJ2727 capsules against placebos for preventing Ulcerative Colitis relapse. It involves taking these orally and monitoring gut microbiota changes over time to see how they relate to clinical outcomes compared with a placebo.
What are the potential side effects?
While specific side effects are not listed here, fecal microbiota transplantation could potentially cause digestive discomforts such as bloating or gas; there's also a risk of infection transmission despite screening donor material.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My ulcerative colitis is in remission and I'm on a stable treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant, breastfeeding, nor planning to become pregnant during the study.
Select...
I cannot take pills in capsule form.
Select...
I have a history of bile acid diarrhea.
Select...
My immune system is weak due to a condition or medication like high-dose prednisone.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Subject-reported score in Hospital Anxiety and Depression Scale

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Patients with UC will receive FMT capsulesExperimental Treatment1 Intervention
Patients with ulcerative colitis will receive fecal microbiota capsules from 3 healthy donors
Group II: Patients with UC will receive placeboPlacebo Group1 Intervention
Patients with ulcerative colitis will receive matching placebo capsules. Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRIM-DJ2727
2019
Completed Phase 1
~20

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Fecal Microbiota Transplantation (FMT) involves transferring stool from a healthy donor to a UC patient's gastrointestinal tract to restore a balanced gut microbiota, thereby reducing inflammation and improving gut health. This is achieved by increasing microbial diversity and promoting the growth of beneficial bacteria. Other common treatments for UC, such as aminosalicylates, corticosteroids, immunomodulators, and biologics, work by reducing inflammation and modulating the immune response. Understanding these mechanisms is crucial for UC patients to select the most appropriate treatment based on disease severity and individual response.

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
949 Previous Clinical Trials
344,967 Total Patients Enrolled

Media Library

PRIM-DJ2727 (Fecal Microbiota Transplantation) Clinical Trial Eligibility Overview. Trial Name: NCT04373473 — Phase 2
Ulcerative Colitis Research Study Groups: Patients with UC will receive FMT capsules, Patients with UC will receive placebo
Ulcerative Colitis Clinical Trial 2023: PRIM-DJ2727 Highlights & Side Effects. Trial Name: NCT04373473 — Phase 2
PRIM-DJ2727 (Fecal Microbiota Transplantation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04373473 — Phase 2
~12 spots leftby Dec 2025